- Patent Title: Bordetella pertussis LOS-derived oligosaccharide with pertussis toxin glycoconjugate and its application in the prophylaxis and treatment of infections caused by Bordetella pertussis
-
Application No.: US14896222Application Date: 2014-06-04
-
Publication No.: US09878051B2Publication Date: 2018-01-30
- Inventor: Sabina Koj , Tomasz Niedziela , Czeslaw Lugowski
- Applicant: WROCLAWSKIE CENTRUM BADAŃ EIT+ SP. Z O.O.
- Applicant Address: PL Wroclaw
- Assignee: WROCLAWSKIE CENTRUM BADAN EIT+ SP. Z O.O.
- Current Assignee: WROCLAWSKIE CENTRUM BADAN EIT+ SP. Z O.O.
- Current Assignee Address: PL Wroclaw
- Agency: Arrigo, Lee & Guttman LLP
- Priority: PL404247 20130607
- International Application: PCT/IB2014/061944 WO 20140604
- International Announcement: WO2014/195881 WO 20141211
- Main IPC: A61K39/02
- IPC: A61K39/02 ; A61K47/48 ; A61K39/00
Abstract:
The present invention relates to an immunogenic and a non-toxic glycoconjugate comprising Bordetella pertussis LOS-derived oligosaccharide and pertussis toxin, a method of preparing such glycoconjugate, the pharmaceutical composition, a vaccine composition containing such glycoconjugate, and an application of the glycoconjugate. The glycoconjugate is prepared as a vaccine component for protection against infections caused by Bordetella pertussis.
Public/Granted literature
Information query
